Helixgate https://validator.w3.org/feed/docs/rss2.html Home AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval Parkinson’s drug from Biogen, Denali comes up short Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival STAT+: EU and US advisers split over AstraZeneca breast cancer drug  Why one health AI unicorn is giving away its service for free Recordati fields $12.4B go-private offer AI Designs Miniprotein Switches for GPCR Targeting STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial STAT+: 3 burning questions senators had for the NIH director AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel  Gilead inks $140M API supply deal, tightening ties to Korean manufacturer STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion A federal office of men’s health has never been closer, yet it’s likely still years away Opinion: Check-in and intake at the doctor’s office are perfect for AI Mass General Brigham says it is saving more lives. Some doctors aren’t so sure. Constructing artificial methylotrophic S. cerevisiae for chondroitin sulfate production using a multidimensional combinatorial strategy #ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China study How To Shine As Biotech Comes Back From the Brink Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Bio-IT World Celebrates 25 Years with Opening Plenary on Rare Disease Challenges and Opportunities AI Model Offers Map of How Genes Work Together in Different Cellular Contexts Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop Guarding biotech from China and big bets in longevity How a group of biotechs ran a covert campaign to push out the FDA commissioner Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos Chutes & Ladders—Former FDA leader takes new biotech Turn STAT+: RFK Jr.’s screen time warning RA Capital banks $75M for a biotech SPAC China’s drugmakers to take the stage at #ASCO26 Novel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs BioMarin notches win in study that could expand use of top-selling medicine Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug BioMarin to seek further approval of Voxzogo in form of short stature Incyte signs AI deals with Genesis Molecular AI, Edison Scientific Live: Senate committee questions NIH director on 2027 budget BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus Lilly’s triple agonist shows bariatric surgery–like weight loss results How Florida hospitals won big in Medicaid funds (just in time) Vaxart seeks shareholder support as battle over stock split brews Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling Lilly’s triple agonist still leads among late-stage obesity assets STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial Inside Germany’s biotech capital infrastructure and innovation engine Opinion: STAT+: Dark times ahead at the FDA Are ‘AI co-scientist’ tools actually useful for scientists? Biopharma professionals increasingly accept underemployment MIT scientists discover amino acid that helps the gut heal itself